Bookmarks
ID-427-1: Detecting and treating CKD at the earliest stages
Safe People
Organisation name
Imperial College Healthcare NHS Trust
Applicant name(s)
Funders/ Sponsors
Safe Projects
Project ID
ID-427
Lay summary
This study’ll evaluate the effectiveness & health benefits for patients prescribed with SGLT2 inhibitors in the earliest phases of being diagnosed with CKD, to assess their impact and understand the true benefits of this class of drugs for CKD patients.
Public benefit statement
The prevalence of chronic kidney disease (CKD) is increasing worldwide. Without interventions for improvement of care, patient-based and healthcare system-based ramifications will result in adverse clinical and financial outcomes. Multiple factors ranging from clinical risk factors, a combination of clinical risk factors, such as multimorbidity, particularly associated with hypertension and Type 2 Diabetes (T2DM), and population health risk factors (e.g. socioeconomic differences) increase the risk of development and progression of this burdensome disease. Another major risk is that patients with CKD are not treated appropriately at the earliest stages of intervention
Other approval committees
Latest approval date
15/05/2025
Safe Data
Dataset(s) name
Safe Setting
Access type
TRE